Diagnostic and Interventional Cardiology

Videos | EP Lab

VIDEO: Antibacterial Envelope for EP Devices Reduced Infections in Patients With Hemotomas by 82 Percent

Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at ...

October 04, 2021

A cardiac scan on the new Siemens Naeotom Alpha. This is the first commercialized photon-counting CT scanner. It gained FDA clearance Sept. 30, 2021. Image by Deutscher Zukunftpreis/Ansgar Pudenz.

Feature | Computed Tomography (CT) | By Dave Fornell, DAIC Editor

First Photon-counting CT System Cleared by the FDA

The U.S. Food and Drug Administration (FDA) Sept. 30 cleared the world's first photon-counting computed tomography (CT) ...

October 04, 2021

News | Antiplatelet and Anticoagulation Therapies

MASTER DAPT Shows 1-month Dual Antiplatelet Therapy After Stent Benefits High Bleeding Risk Patients

October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...

October 04, 2021

Sponsored Content

Case Study | Cardiovascular Information Systems (CVIS)

Single-Database Cardiology Platform Drives Efficient Workflow and Improves Data Access

Washington Health System (WHS) provides healthcare services at more than 40 offsite locations across three counties in ...

April 01, 2021

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline).

Feature | EP Lab

Radiation Therapy Reprograms Heart Cells to Younger State

September 28, 2021 — New research from Washington University School of Medicine in St. Louis suggests that radiation ...

September 28, 2021

Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a personal medical device kit, Biokit, that includes a bundled of home-use devices to monitor cardiovascular disease. It includes a digital thermometer, a pulse oximeter and a blood pressure cuff. All three devices are U.S. FDA cleared, wireless, wearable, and integrate into the Biotricity ecosystem, a platform for interconnectivity.

News | Cardiac Diagnostics

Biotricity Releases Biokit With Three Home Monitoring Devices for Cardiac Disease Management

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

September 28, 2021

Videos | Structural Heart

VIDEO: Roles of the Melody and Harmony Transcatheter Pulmonary Valves in Congenital Heart Disease

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

September 28, 2021

Sponsored Content

COVID-19 has posed challenges for physicians whose cardiac patients are at-risk and reluctant to schedule an office visit. Floyd Russak, M.D., of Russak Personalized Medicine, an internal medicine physician practicing in Greenwood Village, Colo., manages many cardiac patients who do not have ready access to a cardiologist

Feature | Wearables

Cardiac Monitoring in the Time of COVID-19: Next Generation Wearable ECG Technology Comes into Its Own

COVID-19 has posed challenges for physicians whose cardiac patients are at-risk and reluctant to schedule an office ...

December 15, 2020

CardioMEMS is a wireless, battery-free sensor that is implanted into the pulmonary artery via a right heart catheterization procedure to transmit pulmonary artery pressures.

News | Heart Failure

GUIDE-HF Trial Shows Hemodynamic Guided Management Benefits Larger Heart Failure Population

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

September 28, 2021

News | Coronavirus (COVID-19)

COVID Long-hauler Symptoms May be Caused by Antibody Attacks on ACE2

September 28, 2021 — A research team at the University of Arkansas for Medical Sciences (UAMS) has identified a ...

September 28, 2021

High-resolution 3-D delayed enhancement MRI of the left atrium can be used for quantification of fibrosis based on relative intensity of contrast enhancement The DECAAF study found this may help determine which patients will benefit from fibrosis ablation combined with PVI, and which ones are best served with the PVI.

News | Atrial Fibrillation

Fibrosis Ablation Shows Promise in AFib With Low Grade Fibrotic Myopathy

September 28, 2021 — Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve ...

September 28, 2021

Sponsored Content

Case Study | Cardiovascular Information Systems (CVIS)

Leveraging the Right Image and Reporting Platform in Cardiology for Optimal Performance and Outcomes

This Frost & Sullivan Executive White Paper explains that digitization is the shift to value-based care and risk-sharing ...

November 23, 2020

Zebra Medical Vision now offers artificial intelligence (A) medical imaging analytics for its cardiac solution HealthCCSng, which enables the quantification of the coronary artery calcium (CAC) on CT scans as an incidental finding. Zebra gained FDA clearance for the product in September 2021.

News | Artificial Intelligence

FDA Clears Zebra Coronary Artery Calcium Solution as Part of Its Population Health Offering

September 27, 2021 — Zebra Medical Vision, the deep-learning medical imaging analytics company, announces its eighth U.S ...

September 27, 2021

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Feature | Left Atrial Appendage (LAA) Occluders

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

September 27, 2021

Test selection should be a shared decision between patient and physician rather than directed by insurers’ test substitution policies, according to a statement published online in the Journal of the American College of Cardiology.[1] The statement summarizes the proceedings of a recent summit convened by the American Society of Nuclear Cardiology (ASNC), leadership of the American College of Cardiology Imaging Council, American Society of Echocardiography (ASE), Society of Cardiovascular Computed Tomography

News | Cardiac Imaging

Cardiovascular Imaging Organizations Denounce Test Substitution by Insurance Companies

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

September 22, 2021

Sponsored Content

Feature | ECG

A Double-Edged Sword: How Over-the-Counter ECG Devices are Impacting Cardiac Care

Apple created a stir when it announced in 2018 that its Apple Watch Series 4 was the first consumer health and fitness ...

March 11, 2020

Cardiothoracic surgeons with UofL Health – Jewish Hospital and the University of Louisville performed the world’s first Carmat Aeson bioprosthetic total artificial heart implantation in a female patient on Sept. 14, 2021. The device was small enough to fit into the woman's smaller chest cavity. The device is being tested as a bridge to heart transplant rather than use of a LVAD. Photo by UofL Health.

News | Heart Failure

First Woman in World Receives New Type of Artificial Heart

September 22, 2021 — A cardiothoracic surgical team with University of Louisville Health – Jewish Hospital has performed ...

September 22, 2021

News | Heart Failure

ESC Releases Guidelines on Heart Failure Management

September 21, 2021 — The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and ...

September 21, 2021

$Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device with Shield Technology, which are transcatheter devices used to seal brain aneurysms. The company said there is a risk of the delivery system’s wire and tubes fracturing and breaking off when the system is being used to place, retrieve, or move the stent inside a patient.$

News | Cath Lab

Medtronic Recalls Neurovascular Pipeline Flex Embolization Devices for Risk of Fractures During Placement, Retrieval or Movement of Device

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

September 21, 2021